AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00768560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat CR, BAYA1040) 80mg OD
Description: Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
Study NCT00768560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat CR, BAYA1040) 40mg BID
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
Study NCT00768560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat CR, BAYA1040) 40mg OD
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
Study NCT01215084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-PR)
Description: A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
Study NCT02015819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli CD-expressing genetically modified neural stem cells
Description: Given intracranially
Study NCT02015819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucytosine
Description: Given orally
Study NCT02015819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given orally
Study NCT02015819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02643758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bifocal soft contact lenses
Study NCT02856126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Study NCT02856126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Study NCT02856126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE regimen
Description: infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
Study NCT02856126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC Regimen
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Study NCT02856126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Sorafenib
Description: Oral Sorafenib, 400mg, Bid
Study NCT02856126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sorafenib
Description: Oral Sorafenib, 400mg, Bid
Study NCT01393028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: Cardiac CT: calcium scan and CT coronary angiography
Study NCT01393028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care according to international guidelines
Study NCT02015819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02473406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha 1
Description: In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
Study NCT04054063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486+ etomidate
Study NCT02473406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
Study NCT02489461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz up to 48 weeks
Study NCT02489461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Antiretroviral therapy up to 96 weeks
Study NCT02489461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Description: Antiretroviral therapy up to 96 weeks
Study NCT01373593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study NCT01373593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01055041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled budesonide and formeterol plus oral montelukast
Description: 1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
Study NCT01055041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled budesonide and formeterol plus oral doxophylline
Description: 1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
Study NCT02906228 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
Study NCT00918450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed
Study NCT02232698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time).
Study NCT02232698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time).
Study NCT03869437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
Study NCT03869437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Standard of care was determined by the investigator
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib oral tablets
Description: Lapatinib is administered orally once daily.
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lapatinib oral tablets
Description: Lapatinib is administered orally once daily.
Study NCT01055041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doubling the dose of inhaled budesonide and formeterol
Description: 1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
Study NCT03265574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
Study NCT04042285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.
Study NCT03263026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin Hydrochloride
Description: R-CHOP + Enzastaurin (Kinenza®) 125 mg
Study NCT03263026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: R-CHOP + placebo
Description: R-CHOP + placebo
Study NCT01272154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)
Study NCT01272154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)
Study NCT02610712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT03671681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
Study NCT03671681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
Study NCT03671681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
Study NCT02217943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Study NCT02217943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Study NCT06789354 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and Physical Exam
Description: All assessments were carried out face-to-face with the same physiotherapist.
Study NCT02253251 — intervention group
Intervention type: GENETIC
Intervention: KRAS-variant and microRNA binding site mutation testing
Description: Participant in these studies will be tested for the KRAS-variant
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chemotherapy
Description: Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
Study NCT00387127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin chemotherapy
Description: Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
Study NCT04008368 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS CD34 Reagent
Description: Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
Study NCT02818257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip A
Description: Adhesive strip A
Study NCT04042285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary
Study NCT03325387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC
Study NCT03325387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01561391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
Study NCT01561391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
Study NCT01561391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: factor IX
Description: Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
Study NCT01561391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: factor VIII
Description: Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
Study NCT03375047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005
Study NCT03375047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline for Inhalation
Study NCT00647686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
Description: single application
Study NCT00647686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Transdermal System 25 mcg/h
Description: single application
Study NCT03699696 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia prior to surgery with propofol
Study NCT04548778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BÜHLMANN fPELA assay
Description: BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
Study NCT01921894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
Study NCT01921894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
Study NCT03351998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 20Mg Tablet
Description: 20 mg/day pills.
Study NCT03351998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 80Mg Tablet
Description: 80 mg/day pills.
Study NCT03351998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo pill.
Study NCT00244764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Study NCT00244764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Study NCT00954590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon (latrepirdine)
Description: 20 mg orally three times daily
Study NCT00954590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally three times daily
Study NCT00223925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Study NCT01961427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
Study NCT01961427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
Study NCT01120626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
Study NCT01120626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
Study NCT00699790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCR2 Antagonist
Description: Tablets, Oral, 50 mg, once daily, 12 weeks
Study NCT02818257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip B
Description: Adhesive strip B
Study NCT00223925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03913065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI).
Study NCT00828295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron IV 1 mcg/kg
Study NCT00828295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron 3mcg/kg IV
Study NCT03902548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P16-129
Description: Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
Study NCT01031394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency of Aerobic/Resistance Training - 3 to 3
Description: comparing group results based upon frequency of exercise
Study NCT00252967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg of Atorvastatin
Study NCT00252967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04292873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Enteral supplement of 569,600 IU vitamin D
Study NCT00905606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Tablets
Study NCT00905606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Tablets
Study NCT00699790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, once daily, 12 weeks
Study NCT02818257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip C
Description: Adhesive strip C
Study NCT03427073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM201
Description: Drug: ALM201 administered subcutaneously
Study NCT03984409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kroger low calorie orange juice beverage
Description: Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved